Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALAN J KIVITZ

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1447259023
CMS profile
291961
Location
DUNCANSVILLE, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$241,489.58

661 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 13 of 14; records 601–650 of 661 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALAN J KIVITZ

NPI 1447259023 · CMS profile ID 291961

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

DUNCANSVILLE, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 13 of 14; records 601–650 of 661 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447259023?year=2019&recipient=provider&page=13#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALAN J KIVITZ, NPI 1447259023, CMS profile ID 291961. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 14; records 601–650 of 661 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447259023?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ALAN J KIVITZ, NPI 1447259023, CMS profile ID 291961. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 14; records 601–650 of 661 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447259023?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ALAN J KIVITZ, NPI 1447259023, CMS profile ID 291961, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 13 of 14; records 601–650 of 661 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1447259023?year=2019&recipient=provider&page=13#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

661 matching records · $241,489.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 661 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 601–650 of 661.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $15.3902/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662154627 CMS
Lilly USA, LLC $258.7402/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657655031 CMS
Lilly USA, LLC $157.6302/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657655033 CMS
PFIZER INC. $5.9702/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672454514 CMS
Celgene Corporation $2,563.0002/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672830709 CMS
Celgene Corporation $6.3802/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672835171 CMS
Celgene Corporation $120.0002/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672835177 CMS
Lilly USA, LLC $15.1602/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657652105 CMS
AbbVie, Inc. $13.2302/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648148165 CMS
Amgen Inc. $16.1402/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662154631 CMS
Celgene Corporation $4.9002/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672731249 CMS
Celgene Corporation $1.2402/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672733555 CMS
Novartis Pharmaceuticals Corporation $12.2801/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659549947 CMS
Horizon Therapeutics plc $8.6601/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691416921 CMS
Novartis Pharmaceuticals Corporation $11.6901/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659549943 CMS
UCB, Inc. $12.4001/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688251489 CMS
AbbVie, Inc. $6.6601/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648148159 CMS
Amgen Inc. $19.3601/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662154603 CMS
GlaxoSmithKline, LLC. $11.1501/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671153191 CMS
Celgene Corporation $6.0601/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672717183 CMS
Celgene Corporation $70.9101/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672835169 CMS
Celgene Corporation $2,563.0001/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673011864 CMS
Amgen Inc. $17.7701/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662154625 CMS
Amgen Inc. $7.4501/22/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663324587 CMS
Horizon Therapeutics plc $17.4701/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691416919 CMS
PFIZER INC. $18.0701/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672453171 CMS
Novartis Pharmaceuticals Corporation $8.6001/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659549941 CMS
Janssen Biotech, Inc. $12.2101/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658529721 CMS
Sobi, Inc $12.3101/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698094475 CMS
AbbVie, Inc. $13.4601/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648148155 CMS
PFIZER INC. $11.3601/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672450228 CMS
PFIZER INC. $780.0001/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672673419 CMS
AbbVie, Inc. $0.1301/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648148147 CMS
Flexion Therapeutics, Inc. $50.0001/14/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705852847 CMS
Celgene Corporation $56.3701/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672833121 CMS
Celgene Corporation $45.1201/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672838855 CMS
Celgene Corporation $5,043.0001/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672843377 CMS
Celgene Corporation $188.6501/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672844128 CMS
Celgene Corporation $157.9501/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672844149 CMS
Celgene Corporation $86.2201/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672844155 CMS
Celgene Corporation $38.9201/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672845831 CMS
Celgene Corporation $53.6801/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672845837 CMS
Celgene Corporation $139.5601/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672859521 CMS
Celgene Corporation $58.0001/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672871563 CMS
Celgene Corporation $19.8001/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672871567 CMS
Celgene Corporation $36.7701/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672871609 CMS
Celgene Corporation $224.8801/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672871615 CMS
Celgene Corporation $56.6601/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672871621 CMS
Alexion Pharmaceuticals, Inc. $15.3901/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695621749 CMS
PFIZER INC. $11.1301/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672457675 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $241,489.58 661
PY2020 $86,460.48 405
PY2021 $131,318.71 366
PY2022 $127,443.84 439
PY2023 $105,631.04 422
PY2024 $138,948.82 522
PY2025 $105,009.88 540

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $509.29 1
PY2025 Principal investigator $5,331,984.99 289
PY2024 Recipient $12,476.88 4
PY2024 Principal investigator $3,675,816.60 217
PY2023 Recipient $5,547.39 4
PY2023 Principal investigator $3,137,369.25 336
PY2022 Recipient $3,324.00 5
PY2022 Principal investigator $3,646,712.77 293
PY2021 Recipient $11,588.00 9
PY2021 Principal investigator $3,875,897.77 384
PY2020 Recipient $34,397.13 32
PY2020 Principal investigator $3,237,261.65 498
PY2019 Recipient $48,731.74 28
PY2019 Principal investigator $3,234,791.65 442

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

290 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $834.57 12/31/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228749030
Principal investigator 1 ModernaTX, Inc. $1,440.00 12/22/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968837
Principal investigator 1 ModernaTX, Inc. $2,846.41 12/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968787
Principal investigator 1 ModernaTX, Inc. $315.31 12/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968797
Principal investigator 1 ModernaTX, Inc. $9,741.40 12/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968819
Principal investigator 1 ModernaTX, Inc. $1,950.00 12/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968849
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,022.95 12/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223290028
Principal investigator 1 ABBVIE INC. $336.00 12/18/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202531150
Principal investigator 1 PFIZER INC. $8,845.70 12/17/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228747193
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,683.95 12/17/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289884
Principal investigator 1 PFIZER INC. $36,262.49 12/16/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228725560
Principal investigator 1 Janssen Research & Development, LLC $500.00 12/15/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175303283
Principal investigator 1 Janssen Research & Development, LLC $7,563.00 12/15/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303384
Principal investigator 1 Janssen Research & Development, LLC $746.26 12/15/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303394
Principal investigator 1 ABBVIE INC. $288.00 12/11/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202530014
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 12/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289332
Principal investigator 1 ABBVIE INC. $3,000.00 12/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1202526440
Principal investigator 1 ABBVIE INC. $1,932.65 12/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202526930
Principal investigator 1 ABBVIE INC. $18,232.32 12/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202526932
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 12/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 12/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 12/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $650.00 12/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269119
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $82.60 12/01/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223288955
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,118.60 12/01/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289118
Principal investigator 1 Janssen Research & Development, LLC $3,135.00 11/27/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175264998
Principal investigator 1 Janssen Research & Development, LLC $68.00 11/27/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265013
Principal investigator 1 Janssen Research & Development, LLC $271.00 11/27/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265033
Principal investigator 1 Janssen Research & Development, LLC $68.00 11/27/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265053
Principal investigator 1 Janssen Research & Development, LLC $2,290.00 11/27/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265168
Principal investigator 1 Janssen Research & Development, LLC $35.00 11/26/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175264980
Principal investigator 1 Janssen Research & Development, LLC $35.00 11/26/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265007
Principal investigator 1 Janssen Research & Development, LLC $35.00 11/26/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265040
Principal investigator 1 Janssen Research & Development, LLC $35.00 11/26/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,376.82 11/25/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184264473
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18.55 11/20/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235999089
Principal investigator 1 Eli Lilly and Company $1,020.92 11/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187874679
Principal investigator 1 Janssen Research & Development, LLC $1,492.52 11/17/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303263
Principal investigator 1 Novartis Pharmaceuticals Corporation $34.15 11/15/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190303117
Principal investigator 1 ABBVIE INC. $549.00 11/13/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202524243
Principal investigator 1 PFIZER INC. $19,360.33 11/13/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228720559
Principal investigator 1 ABBVIE INC. $992.00 11/12/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202523889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $282.92 11/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,644.00 11/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,911.00 11/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258885
Principal investigator 1 ABBVIE INC. $10,215.56 11/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202522647
Principal investigator 1 GlaxoSmithKline, LLC. $2,507.40 11/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192147855
Principal investigator 1 ABBVIE INC. $3,669.30 11/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202520873
Principal investigator 1 Janssen Research & Development, LLC $600.00 10/31/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303233
Principal investigator 1 Janssen Research & Development, LLC $430.86 10/30/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175303249
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 10/30/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175303401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,188.41 10/29/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253560
Principal investigator 1 Janssen Research & Development, LLC $651.78 10/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175303256
Principal investigator 1 ModernaTX, Inc. $3,080.37 10/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968815
Principal investigator 1 ModernaTX, Inc. $4,169.90 10/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968823
Principal investigator 1 ModernaTX, Inc. $6,621.51 10/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,984.52 10/23/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252468
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 10/22/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCHPC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223287245
Principal investigator 1 ABBVIE INC. $168.00 10/16/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202517267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,619.03 10/16/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250595
Principal investigator 1 ABBVIE INC. $5,452.10 10/09/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202513741
Principal investigator 1 ABBVIE INC. $4,257.94 10/09/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202515547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,568.40 10/09/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184248862
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,777.05 10/03/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244523
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,150.00 10/01/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286049
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 09/25/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175303242
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 09/25/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175303332
Principal investigator 1 Janssen Research & Development, LLC $160.00 09/25/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175303366
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,055.91 09/23/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241828
Principal investigator 1 Janssen Research & Development, LLC $989.92 09/22/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175303298
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,911.92 09/18/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240822
Principal investigator 1 ModernaTX, Inc. $500.00 09/15/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84,218.09 09/10/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235843
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 09/10/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223285253
Principal investigator 1 ABBVIE INC. $12,500.00 09/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202508950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,152.30 09/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235359
Principal investigator 1 ABBVIE INC. $1,509.50 09/03/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202507461
Principal investigator 1 ModernaTX, Inc. $265.20 09/01/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,112.64 08/26/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $506.35 08/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229715
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,510.45 08/20/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223284383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,937.92 08/14/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228281
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 08/11/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192181636
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 08/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A PHASE IB, DOSE ESCALATION, OPEN LABEL STUDY TO EVALUATE THE SAFETY, No dispute reported 06/30/2026 1192181640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,519.05 08/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,555.00 08/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 08/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,911.00 08/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,250.00 08/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226117
Principal investigator 1 PFIZER INC. $480.00 08/06/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228767259
Principal investigator 1 ABBVIE INC. $4,831.80 08/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202501346
Principal investigator 1 GlaxoSmithKline, LLC. $2,507.40 08/01/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192181631
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,608.25 08/01/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223283421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.70 07/31/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222744
Principal investigator 1 Amgen Inc. $1,437.84 07/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH - 175 MEADOWBROOK LN
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639083
Principal investigator 1 ModernaTX, Inc. $1,026.79 07/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968781
Principal investigator 1 ModernaTX, Inc. $290.08 07/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968783
Principal investigator 1 ModernaTX, Inc. $315.31 07/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968801
Principal investigator 1 SANOFI US SERVICES INC. $5,350.00 07/28/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research PC Corp
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226137059
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/23/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265133
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/23/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265155
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/23/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265223
Principal investigator 1 PFIZER INC. $375.98 07/23/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228763720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,863.14 07/22/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,822.00 07/22/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,822.00 07/22/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125.34 07/22/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.86 07/22/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,911.00 07/22/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217633
Principal investigator 1 UCB SA $6,381.60 07/21/2025 Non-covered Recipient Entity
WEITZNER, YONKER, KAINE MD.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657870
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,444.27 07/17/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217000
Principal investigator 1 PFIZER INC. $108.00 07/16/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228765238
Principal investigator 1 ModernaTX, Inc. $1,760.00 07/14/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968817
Principal investigator 1 PFIZER INC. $8,537.98 07/11/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228773516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,257.42 07/10/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214266
Principal investigator 1 ABBVIE INC. $1,200.00 07/09/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202497598
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/03/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303324
Principal investigator 1 ABBVIE INC. $13,500.00 07/02/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202494927
Principal investigator 1 ABBVIE INC. $4,042.90 07/02/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202495897
Principal investigator 1 SANOFI US SERVICES INC. $9,063.00 07/02/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research PC Corp
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226137036
Principal investigator 1 Janssen Research & Development, LLC $68.00 06/30/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265150
Principal investigator 1 Janssen Research & Development, LLC $2,757.00 06/30/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265182
Principal investigator 1 ModernaTX, Inc. $772.20 06/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968791
Principal investigator 1 ModernaTX, Inc. $10,089.92 06/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968793
Principal investigator 1 ModernaTX, Inc. $4,115.51 06/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968839
Principal investigator 1 ModernaTX, Inc. $18,482.22 06/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968845
Principal investigator 1 Novartis Pharmaceuticals Corporation $142.66 06/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190303115
Principal investigator 1 UCB SA $7,335.25 06/27/2025 Covered Recipient Physician A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 1246658592
Principal investigator 1 PFIZER INC. $27,880.36 06/21/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228793183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,012.70 06/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209129
Principal investigator 1 Aurinia Pharma U.S., Inc. $1,900.00 06/18/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research, PC
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930838
Principal investigator 1 SANOFI US SERVICES INC. $2,200.00 06/16/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research PC Corp
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226137013
Principal investigator 1 SANOFI US SERVICES INC. $17,706.40 06/16/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research PC Corp
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226137017
Principal investigator 1 SANOFI US SERVICES INC. $14,990.00 06/16/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research PC Corp
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226137025
Principal investigator 1 Janssen Research & Development, LLC $1,800.00 06/13/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,197.14 06/12/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206205
Principal investigator 1 PFIZER INC. $41,212.68 06/06/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228776985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,269.73 06/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204139
Principal investigator 1 UCB SA $12,489.00 06/04/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658610
Principal investigator 1 ABBVIE INC. $1,255.15 06/03/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202487427
Principal investigator 1 Janssen Research & Development, LLC $68.00 05/28/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265094
Principal investigator 1 Janssen Research & Development, LLC $2,316.00 05/28/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,119.78 05/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,466.00 05/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,733.00 05/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8.25 05/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223280450
Principal investigator 1 Eli Lilly and Company $2,036.86 05/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187874427
Principal investigator 1 Eli Lilly and Company $4,314.00 05/23/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,292.70 05/22/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197551
Principal investigator 1 Amgen Inc. $4,275.18 05/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246639087
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,118.60 05/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223280102
Principal investigator 1 Janssen Research & Development, LLC $16,000.00 05/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303307
Principal investigator 1 Janssen Research & Development, LLC $600.00 05/15/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303274
Principal investigator 1 Janssen Research & Development, LLC $600.00 05/15/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303358
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,487.89 05/15/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194605
Recipient Novartis Pharmaceuticals Corporation $509.29 05/13/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190293790
Principal investigator 1 GlaxoSmithKline, LLC. $2,507.40 05/09/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192147851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,163.00 05/08/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193727
Principal investigator 1 Aurinia Pharma U.S., Inc. $155.00 05/07/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research, PC
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930761
Principal investigator 1 Aurinia Pharma U.S., Inc. $2,700.00 05/07/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research, PC
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930763
Principal investigator 1 ABBVIE INC. $8,632.35 05/06/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202481237
Principal investigator 1 PFIZER INC. $72,623.06 04/29/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228794089
Principal investigator 1 Eli Lilly and Company $38,760.00 04/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874429
Principal investigator 1 ModernaTX, Inc. $17,026.74 04/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968805
Principal investigator 1 ModernaTX, Inc. $12,158.64 04/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968809
Principal investigator 1 ModernaTX, Inc. $4,278.68 04/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968811
Principal investigator 1 ModernaTX, Inc. $3,001.17 04/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968833
Principal investigator 1 ModernaTX, Inc. $772.20 04/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968835
Principal investigator 1 ModernaTX, Inc. $217.62 04/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,059.89 04/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,224.90 04/23/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189147
Principal investigator 1 ModernaTX, Inc. $1,750.00 04/16/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,328.79 04/15/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183454
Principal investigator 1 ModernaTX, Inc. $576.69 04/11/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968803
Principal investigator 1 ModernaTX, Inc. $195.55 04/11/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968841
Principal investigator 1 PFIZER INC. $77,252.64 04/10/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228794187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,895.26 04/08/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184182068
Principal investigator 1 Eli Lilly and Company $245,665.29 04/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND CHRONIC LOW BACK PAIN (TRIUMPH-7) No dispute reported 06/30/2026 1187876223
Principal investigator 1 ABBVIE INC. $1,328.45 04/03/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202471243
Principal investigator 1 PFIZER INC. $1,878.80 04/01/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228779460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,881.35 04/01/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,911.00 04/01/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.32 04/01/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180922
Principal investigator 1 UCB SA $13,000.00 03/27/2025 Non-covered Recipient Entity
WEITZNER, YONKER, KAINE MD.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,447.79 03/25/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178878
Principal investigator 1 Eli Lilly and Company $361,518.90 03/24/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY No dispute reported 06/30/2026 1187876221
Principal investigator 1 Amgen Inc. $3,626.28 03/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH - 175 MEADOWBROOK LN
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome No dispute reported 06/30/2026 1246639079
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,520.00 03/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223276943
Principal investigator 1 UCB SA $14,043.00 03/21/2025 Non-covered Recipient Entity
WEITZNER, YONKER, KAINE MD.
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 1246658372
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,233.60 03/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $201.39 03/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $657.96 03/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,911.00 03/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35.20 03/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,911.00 03/19/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174600
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,000.00 03/14/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223276731
Principal investigator 1 Aurinia Pharma U.S., Inc. $2,146.50 03/12/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research, PC
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930990
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,541.00 03/11/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus No dispute reported 06/30/2026 1235999085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,875.00 03/11/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170902
Principal investigator 1 Janssen Research & Development, LLC $4,423.00 03/10/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175303340
Principal investigator 1 Janssen Research & Development, LLC $16,000.00 03/10/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175303375
Principal investigator 1 ABBVIE INC. $4,780.60 03/06/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202456965
Principal investigator 1 Janssen Research & Development, LLC $2,635.00 03/05/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175264947
Principal investigator 1 Janssen Research & Development, LLC $68.00 03/05/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175264956
Principal investigator 1 Janssen Research & Development, LLC $68.00 03/05/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175264973
Principal investigator 1 Janssen Research & Development, LLC $2,635.00 03/05/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265046
Principal investigator 1 Janssen Research & Development, LLC $2,635.00 03/05/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265076
Principal investigator 1 Janssen Research & Development, LLC $68.00 03/05/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265125
Principal investigator 1 Janssen Research & Development, LLC $68.00 03/05/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265141
Principal investigator 1 Janssen Research & Development, LLC $2,635.00 03/05/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265162
Principal investigator 1 Janssen Research & Development, LLC $68.00 03/05/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265200
Principal investigator 1 Janssen Research & Development, LLC $2,635.00 03/05/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,996.38 03/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156766
Principal investigator 1 UCB SA $53.89 02/27/2025 Non-covered Recipient Entity
WEITZNER, YONKER, KAINE MD.
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 1246658442
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15.00 02/25/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus No dispute reported 06/30/2026 1235999083
Principal investigator 1 Eli Lilly and Company $2,472.72 02/25/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187872941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,336.34 02/25/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155388
Principal investigator 1 Janssen Research & Development, LLC $35.00 02/24/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265060
Principal investigator 1 Janssen Research & Development, LLC $500.00 02/24/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265068
Principal investigator 1 Janssen Research & Development, LLC $35.00 02/24/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265191
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,545.00 02/20/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190306179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,443.85 02/18/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,400.00 02/13/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 02/13/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153916
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 02/13/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $59.07 02/13/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.80 02/13/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153922
Principal investigator 1 ABBVIE INC. $4,056.85 02/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202444606
Principal investigator 1 AstraZeneca UK Limited $21,161.15 02/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185546153
Principal investigator 1 ModernaTX, Inc. $2,000.00 02/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968795
Principal investigator 1 ModernaTX, Inc. $800.00 02/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968831
Principal investigator 1 ModernaTX, Inc. $7,000.00 02/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968847
Principal investigator 1 PFIZER INC. $1,240.00 02/05/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228762273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,228.81 02/05/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152430
Principal investigator 1 ABBVIE INC. $1,800.00 02/04/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202443739
Principal investigator 1 Janssen Research & Development, LLC $16,000.00 02/03/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303290
Principal investigator 1 Janssen Research & Development, LLC $750.00 02/03/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEAR CH PC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175303348
Principal investigator 1 Eli Lilly and Company $1,157.44 01/31/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187872939
Principal investigator 1 Eli Lilly and Company $661.22 01/31/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187875563
Principal investigator 1 Novartis Pharmaceuticals Corporation $39,822.00 01/30/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190306181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,330.02 01/29/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149846
Principal investigator 1 UCB SA $72,121.00 01/29/2025 Non-covered Recipient Entity
WEITZNER, YONKER, KAINE MD.
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657380
Principal investigator 1 Eli Lilly and Company $7,810.00 01/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875853
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,620.76 01/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190306019
Principal investigator 1 Novartis Pharmaceuticals Corporation $229,384.33 01/28/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190306183
Principal investigator 1 Eli Lilly and Company $3,025.22 01/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875565
Principal investigator 1 ModernaTX, Inc. $2,026.44 01/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968779
Principal investigator 1 ModernaTX, Inc. $1,487.07 01/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968799
Principal investigator 1 ModernaTX, Inc. $634.55 01/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968807
Principal investigator 1 ModernaTX, Inc. $3,468.41 01/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968813
Principal investigator 1 ModernaTX, Inc. $18,007.02 01/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968821
Principal investigator 1 ModernaTX, Inc. $772.20 01/27/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968827
Principal investigator 1 UCB SA $900.00 01/27/2025 Non-covered Recipient Entity
WEITZNER, YONKER, KAINE MD.
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246657085
Principal investigator 1 PFIZER INC. $240.00 01/25/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228798861
Principal investigator 1 PFIZER INC. $2,045.12 01/22/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228802068
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,675.78 01/21/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus No dispute reported 06/30/2026 1235999081
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $299.59 01/21/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235999091
Principal investigator 1 Eli Lilly and Company $143,170.00 01/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187871955
Principal investigator 1 Eli Lilly and Company $131,215.00 01/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187874431
Principal investigator 1 Eli Lilly and Company $26,062.00 01/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874433
Principal investigator 1 Eli Lilly and Company $125,103.00 01/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) No dispute reported 06/30/2026 1187880661
Principal investigator 1 Novartis Pharmaceuticals Corporation $961,365.84 01/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190303113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,700.48 01/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149048
Principal investigator 1 UCB SA $420.56 01/21/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH - RESEARCH
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,565.62 01/17/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148079
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $81,650.00 01/16/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235999093
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,022.17 01/15/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) No dispute reported 06/30/2026 1190306185
Principal investigator 1 PFIZER INC. $500.00 01/15/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228800523
Principal investigator 1 Amgen Inc. $1,278,572.61 01/14/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH - 175 MEADOWBROOK LN
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639085
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,554.00 01/13/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1235999087
Principal investigator 1 Janssen Research & Development, LLC $3,135.00 01/13/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175264931
Principal investigator 1 Janssen Research & Development, LLC $160.00 01/13/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175264940
Principal investigator 1 Janssen Research & Development, LLC $2,757.00 01/13/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175264965
Principal investigator 1 Janssen Research & Development, LLC $68.00 01/13/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175264992
Principal investigator 1 Janssen Research & Development, LLC $2,316.00 01/13/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265022
Principal investigator 1 Janssen Research & Development, LLC $271.00 01/13/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265085
Principal investigator 1 Janssen Research & Development, LLC $68.00 01/13/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265109
Principal investigator 1 Janssen Research & Development, LLC $68.00 01/13/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265116
Principal investigator 1 Janssen Research & Development, LLC $160.00 01/13/2025 Non-covered Recipient Entity
Altoona Spclty Ctr Llc
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175265207
Principal investigator 1 SANOFI US SERVICES INC. $3,704.62 01/13/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research PC Corp
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226136969
Principal investigator 1 Eli Lilly and Company $141.90 01/09/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874323
Principal investigator 1 Novartis Pharmaceuticals Corporation $68,580.00 01/09/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190303119
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,953.03 01/09/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190303121
Principal investigator 1 PFIZER INC. $4,172.85 01/09/2025 Non-covered Recipient Entity
Altoona Center for Clinical Research PC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228799624
Principal investigator 1 Amgen Inc. $25,038.06 01/08/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH - 175 MEADOWBROOK LN
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246639081
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $39,115.00 01/08/2025 Non-covered Recipient Entity
Altoona Center For Clinical Research
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235999095
Principal investigator 1 Eli Lilly and Company $72,941.00 01/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187876219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,860.69 01/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,700.48 01/07/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARCH PC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145780
Principal investigator 1 ABBVIE INC. $3,650.40 01/02/2025 Non-covered Recipient Entity
ALTOONA CENTER FOR CLINICAL RESEARC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202434295